Bladder Preservation Yields Poorer Survival in Urothelial Carcinoma
In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study.
Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study.
Immediate Chemotherapy After TURBT Reduces NMIBC Recurrence Risk
An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non–muscle-invasive bladder cancer (NMIBC).
TERT Urine Test Can Help Predict Bladder Cancer Recurrence
A urine test of telomerase reverse transcriptase (TERT) was found to be a reliable predictor of recurrence in non–muscle-invasive bladder cancer, according to a new study.
Physical Inactivity Linked to Kidney, Bladder Cancers
Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers.
First-Line Pembrolizumab for Urothelial Carcinoma Offers Durable Responses
After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.
Epacadostat/Pembrolizumab Promising in Advanced Bladder Cancer in Early Trial
The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.
Options in BCG-Refractory Bladder Cancer for Radical Cystectomy–Ineligible Patients
This video examines second-line treatment options for non-muscle invasive bladder cancer patients who relapse after BCG therapy and are not eligible for radical cystectomy.
Biomarkers Could Predict Bladder Cancer Progression
This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.
Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.